Pioglitazone: A review of Japanese clinical studies

Current Medical Research and Opinion

Volumn 17, Issue 3, 2001, Pages 166-189

  Baba, S ^a  

^a Tokiwa Bldg   (Japan)

Author keywords

Free fatty acids; Glucose; HbAlc; HDL; Insulin resistance; LDL; Pioglitazone; Thiazolidinedione; Total cholesterol; Triglyceride; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; FATTY ACID; GLIBENCLAMIDE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035661219     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990152673819     Document Type: Review

References (15)

1. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
2. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
3. Biological equivalence study of AD-4833 30 mg tablets and 15 mg tablets
4. Clinical Phase 1 study of AD-4833: Single-dose and repeated-dose studies
5. Pharmacokinetic study of AD-4833 in the elderly
6. Clinical pharmacology of long-term treatment with AD-4833 - A study on the effects of the drug concentrations and blood glucose levels
7. Clinical evaluation of AD-4833 on the diurnal changes of blood glucose
8. Concomitant administration of an insulin-resistance improving drug, AD-4833, with SU drugs - Influence on the serum concentrations of SU drugs
9. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus (NIDDM) on diet therapy alone
10. Clinical evaluation of an insulin resistance-improving drug, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone
11. Dose finding study of AD-4833 in patients with NIDDM on diet therapy alone - Double-blind comparative study on four dosages
12. Clinical usefulness of long-term treatment with AD-4833 of patients with non-insulin-dependent diabetes mellitus (NIDDM): Phase III study on long-term treatment
13. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus (NIDDM) on treatment with an SU drug. A placebo-controlled double-blind clinical study
14. Dose finding study of AD-4833 in NIDDM patients on treatment with a sulfonylurea drug - Single-blind comparative study on four dosages
15. Clinical evaluation of an insulin-resistance improving drug, AD-4833, in patients with non-insulin-dependent diabetes mellitus by concomitant administration with Basen® tablets - An open-labeled phase III study